
    
      The crossover study consists of two treatment periods of 15 days duration. On Day 1 of
      Treatment Period 1, eligible patients will be randomised (1:1) to a sequence of treatments
      (either Lu AG06466-placebo or placebo-Lu AG06466). 15 patients are planned per sequence.
    
  